UM Guidelines

	Clinical Indications added/removed the following:
	Current Role Remains Uncertain. [Multiple Cancers, Including Cancer Syndromes (Hereditary) - Gene Panels (less than or equal to 100 genes) may be indicated when ALL of the following are met: The member has a personal history, family history, tumor characteristic, or clinical phenotype suggestive of a hereditary cancer syndrome; and The requested genes are relevant to the member's documented clinical presentation, cancer history, family history, or suspected hereditary cancer syndrome; and Testing results are expected to directly impact clinical management, surveillance, treatment selection, risk-reducing interventions, or family risk assessment; and Documentation demonstrates that a syndrome-specific test or smaller targeted panel would not adequately evaluate the suspected hereditary cancer condition.] * [Examples of Panels Reviewed Under This Guideline The following examples are included but not limited to: Tempus xG+ CancerNext Expanded CancerNext Expanded + RNAinsight Invitae Multi-Cancer Panel Empower Comprehensive MyRisk Comprehensive Custom hereditary cancer panels evaluating multiple unrelated hereditary cancer syndromes] * Evidence Summary Inconclusive or Non-Supportive Evidence [Large hereditary cancer panels (greater than 100 genes) are considered investigational when one or more of the following apply: Testing is performed as broad history-agnostic screening without a documented hereditary cancer syndrome, phenotype, personal cancer history, or family history supporting evaluation The panel evaluates multiple unrelated hereditary cancer syndromes that are not supported by the member's clinical presentation Testing substantially exceeds what is required to evaluate the documented phenotype or suspected syndrome The panel includes numerous genes without established clinical utility, clinical validity, or management recommendations Documentation does not support a syndrome-specific indication for the requested testing.] *